News from nanoscope therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 25, 2022, 07:00 ET Nanoscope Therapeutics Announces First Patient Dosed in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...

Jul 14, 2022, 10:30 ET Nanoscope Therapeutics Receives Spotlight in Breakthrough Technologies Award at OIS Retina Innovation Summit

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...

Jul 12, 2022, 07:00 ET Nanoscope's Gene Therapy to Restore Vision in Patients to be Featured at OIS Retina Innovation Summit and American Society of Retina Specialists Annual Meeting

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...

Jul 11, 2022, 07:00 ET Nanoscope's Top Executive Team to Participate and Present at World Orphan Drug Congress USA Meeting

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...

Jul 05, 2022, 07:00 ET Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today...

Jun 27, 2022, 07:00 ET Nanoscope Therapeutics CEO Sulagna Bhattacharya Named Winner of EY Entrepreneur Of The Year® 2022 Central Plains Award

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today...

Jun 13, 2022, 07:00 ET Nanoscope Therapeutics to Provide Update on Optogenetic Approaches for Vision Restoration at BIO International

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today...

Jun 06, 2022, 07:00 ET Nanoscope's Clinical Development of Optogenetics for Retinal Diseases to be Featured at Macula Society Meeting

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases,...

May 25, 2022, 07:00 ET Nanoscope Therapeutics Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today...

May 13, 2022, 07:00 ET Nanoscope's Clinical and Scientific Advances in Optogenetics to be Featured at ASGCT Annual Meeting, May 16-19, 2022 in Washington, DC

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases,...

Apr 26, 2022, 07:00 ET Nanoscope's Vision Restoring Optogenetic Gene Therapy to be Featured in Multiple Presentations as part of ARVO Annual Meeting in Denver May. 1-4, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases,...

Apr 18, 2022, 07:00 ET Nanoscope Therapeutics Appoints Pharma Industry Veteran Aaron Osborne, MBBS, as Chief Medical Officer and Chief Development Officer

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, today announced Aaron Osborne,...

Apr 04, 2022, 08:57 ET Nanoscope Therapeutics Announces 3 New Appointments to its Scientific and Clinical Advisory Board

Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced...

Mar 28, 2022, 07:00 ET Nanoscope President to Present at Advancing Gene Therapy Summit March 30, 2022, in Boston, MA

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies to treat retinal degenerative diseases,...

Feb 17, 2022, 07:00 ET Nanoscope Therapeutics CEO Sulagna Bhattacharya Elected to BIO Emerging Companies Section Governing Board

Nanoscope Therapeutics Inc., a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the...

Feb 11, 2022, 07:00 ET Nanoscope Therapeutics to present at 2022 BIO CEO & Investor Conference

Nanoscope Therapeutics Inc., today announced that CEO Sulagna Bhattacharya will present at the BIO CEO & Investor Conference, Tuesday, February 15 at ...

Feb 07, 2022, 07:00 ET Nanoscope Therapeutics Announces Completed Enrollment of its Phase 2b Clinical Trial in Blind Patients for Optogenetic Gene Therapy to Restore Vision

Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full...

Feb 01, 2022, 07:00 ET Nanoscope Therapeutics Announces Five New Clinical and Scientific Advisory Board Appointments

Nanoscope Therapeutics Inc, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced an...

Jan 25, 2022, 07:00 ET Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patients

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced it...

Jan 19, 2022, 11:42 ET Nanoscope's Vision Restoring Optogenetic Gene Therapy to be Featured in Four Presentations as part of SPIE Photonics West 2022 in San Francisco Jan. 22-27, 2022

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for the treatment of retinal degenerative...

Jan 10, 2022, 09:45 ET Nanoscope Awarded Key U.S. Patent Protecting its Multi-Characteristic Opsin Gene Therapy Platform For Reversing Blindness

Nanoscope Therapeutics Inc, a clinical-stage biotechnology company developing optogenetic gene therapies for retinal degenerative diseases, today...

Dec 08, 2021, 08:30 ET Nanoscope Therapeutics' Optogenetic Gene Therapy to be Featured in Presentation at Stanford University's Innovate Retina Summit Dec. 11, 2021

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative...

Dec 03, 2021, 07:00 ET Nanoscope Therapeutics Wins 'Top Retina Company' Award at 2021 Eyecelerator Conference for Its Optogenetics Gene Therapy to Restore Vision in People Blinded by Retinal Diseases

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative...

Nov 15, 2021, 07:00 ET Nanoscope Therapeutics co-Founder and President to Present at World Orphan Drug Congress Europe 2021, Nov. 17, in Barcelona, Spain

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative...

Nov 09, 2021, 07:00 ET Nanoscope President to Present at Eyecelerator during the American Academy of Ophthalmology 2021 Annual Meeting, Nov. 11, in New Orleans, LA

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative...